Alexander E Perl, MD
Gilteritinib (Xospata) has the potential to reshape the treatment paradigm for patients with FLT3
-positive acute myeloid leukemia (AML), according to Alexander E. Perl, MD, a leading investigator into the drug.
The FDA approved gilteritinib, a small molecule that inhibits FLT3 and other kinases, as single-agent therapy for patients with relapsed/refractory AML harboring a FLT3
mutation based on remission rates in the phase III ADMIRAL trial (NCT02421939).
In an interview with OncologyLive®
, Perl, associate professor in the Division of Hematology/Oncology at the Perelman School of Medicine and a member of the Abramson Cancer Center, both at the University of Pennsylvania in Philadelphia, discussed gilteritinib’s place in the AML landscape and its potential future in the frontline setting.
... to read the full story